| CKI | cyclin-dependent kinase inhibitor |
|---|---|
| CLI | complement lysis inhibitor; corpus luteum insufficiency |
| CPI | California Personality Inventory; Cancer Potential Index; congenital palatopharyngeal incompetence; ... |
| EI | Edmonton injector; electrolyte imbalance; electron impact; electron ionization; emotionally impaired... |
| EIPS | endogenous inhibitor of prostaglandin synthase |
| trypsin inhibitor, kazal pancreatic | <chemical> A pancreatic trypsin inhibitor common to all mammals. It is secreted with the zymogens into the pancreatic juice. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the kunitz bovine pancreatic trypsin inhibitor (aprotinin). Chemical name: Trypsin inhibitor, pancreatic secretory (12 Dec 1998) |
|---|---|
| trypsin inhibitor, kunitz soybean | <chemical> A high-molecular-weight protein (approximately 22,500) containing 198 amino acid residues. It is a strong inhibitor of trypsin and human plasmin. Pharmacological action: trypsin inhibitors. Chemical name: Trypsin inhibitor, Kunitz soybean (12 Dec 1998) |
| familial lipoprotein lipase inhibitor | An inhibitor found in certain individuals that inhibits lipoprotein lipase resulting in accumulation of chylomicrons, VLDL, and triacylglycerols; similar in symptoms to familial lipoprotein lipase deficiency. (05 Mar 2000) |
| lipoprotein-associated coagulation inhibitor | Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex. (05 Mar 2000) |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |